Business
Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease
Expansion improves access to treatment options within periodontal care and helps strengthen partn...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal DiseaseExpansion improves access to treatment options within periodontal care and helps strengthen partnerships with dental professionals within these populations. LAVAL, QC / ACCESS Newswire / November 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company, and OraPharma, its dental products business, today announced the commercial expansion of OraPharma into Canada and Puerto Rico. This strategic move reflects OraPharma's commitment to improving oral health awareness, providing access to treatments within periodontal disease management, and strengthening partnerships with local distributors and dental professionals in these markets.Periodontal disease continues to be one of the most prevalent chronic oral conditions worldwide. Findings from the Global Burden of Disease Study (2021) reveal that over 1 billion people are affected globally.1 In Canada, the Canadian Dental Association estimates that seven in ten Canadians will develop gum disease during their lifetime.2 In Puerto Rico, 44.5% of older adults are living with moderate to severe periodontal disease.3 These figures highlight the urgent need for greater awareness and improved access to treatment options.For more than two decades, OraPharma has been dedicated to helping advance periodontal care. Its flagship product, Arestin®, is the only Food and Drug Administration (FDA) approved locally applied antibiotic for use with scaling and root planing (SRP) as part of periodontal disease management and is supported by over 20 years of clinical experience. Arestin is indicated as an adjunct to SRP for pocket depth reduction in adult periodontitis, helping dental professionals in delivering comprehensive care. This expansion into Canada and Puerto Rico is intended to improve access to periodontal care in these areas.\"OraPharma remains committed to addressing periodontal disease, a condition that affects more than 1 billion globally,\" said Tom Stern, Vice President and General Manager, OraPharma, Bausch Health. \"By expanding access to Arestin in Canada and Puerto Rico, we aim to help address the gaps in care and provide dental professionals with a treatment option to support improved oral health for their adult perio...